AI Summary
Advancements in clinical trials have resulted in many treatment options for MS, but the best practices for using these treatments are still being researched and debated, particularly in regards to when and how to start disease-modifying therapies.
Over the past decades, clinical trial successes have led to a profusion of treatment options for multiple sclerosis (MS), while evolving consensus definitions of disease have allowed for earlier diagnosis. Best practices for using these treatment options have yet to be fully defined and adopted. Particularly, the timing of when disease-modifying therapies (DMTs) should be initiated and the sequencing of DMTs are areas of ongoing research and controversy.